ALK gains important approval on difficult US market
Allergy company ALK has received the green light from the FDA to expand the use of its ragweed allergy tablet to include children. The approval is "significant" on the US market, where ALK has yet to make its big breakthrough.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
The US Food and Drug Administration (FDA) had good news for ALK on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
ALK has decent growth forecast in sight
For subscribers
